How memory T cells affect lung transplant rejection
Official title: Impact of tissue resident memory T cells on chronic rejection after lung transplantation
Funded at University of Pittsburgh at Pittsburgh · NIH-10888252 · Data updated 2026-11-12
This study is looking at how certain immune cells in the lungs might cause problems for people who have had a lung transplant, specifically focusing on a condition called bronchiolitis obliterans syndrome, and it hopes to find ways to improve care for those patients by learning more about these cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | July 1, 2020 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $166,680 |
| NIH project number | 5K23HL151759-05 |
| Project ID | NIH-10888252 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have undergone lung transplantation or are awaiting a lung transplant.
✕Less likely to help
Patients who have not received a lung transplant or those with other unrelated chronic conditions may not benefit from this research.
What this research studies
This research investigates the role of tissue resident memory T cells in the chronic rejection process following lung transplantation. It aims to understand how these immune cells contribute to bronchiolitis obliterans syndrome, a serious condition that affects many lung transplant recipients. By studying the persistence and generation of these T cells, the research seeks to uncover mechanisms that could lead to better management of chronic lung allograft dysfunction. Patients may be involved in providing samples or data to help advance this important area of immunology.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for preventing chronic rejection in lung transplant patients.
How similar studies have gone: Previous research has shown promising results in understanding immune responses in transplant settings, indicating that this approach could yield valuable insights.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Snyder, Mark Eugene — University of Pittsburgh at Pittsburgh
- Study coordinator: Snyder, Mark Eugene
Related research
Other NIH-funded projects on the same topics.
-
Phase 1 trial of siltuximab for antibody-mediated rejection after lung transplant
A early-stage study tests whether siltuximab can help people who have antibody-mediated rejection after lung transplantation.
-
Targeted delivery of immune-suppressing agents to the lung graft to prevent rejection
A study at Northwestern University will test a new, targeted approach to prevent lung transplant rejection by delivering immune-suppressing drugs directly to the graft while blocking early signals that trigger rejection.
-
Siltuximab for antibody-mediated rejection after lung transplant
This trial gives siltuximab to people with antibody-mediated rejection after a lung transplant to try to control the immune response harming the new lung.
-
Role of plasma cells in chronic rejection after lung transplantation
This research looks at how certain immune cells called plasma cells may drive chronic rejection in people who have had lung transplants and how this could lead to new ways to protect the transplant.
-
Non-invasive infection detection after lung transplant
A non-invasive blood test using phage-based signals could help doctors detect lung infections early in people who have had a lung transplant.
-
Investigating the role of plasma cells in lung transplant rejection
This study is looking at how certain immune cells, called plasma cells, might play a role in lung transplant rejection, especially for patients dealing with bronchiolitis obliterans syndrome, and it hopes to find new ways to help improve the success of lung transplants.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.